Synthetic organic

carbinoxamine.

Carbocyclic Thromboxane A2(CTA2) is a stable analog of TXA2 which acts as a potent coronary vasoconstrictor at low concentrations. Unlike other vascular TP receptor agonists, CTA2 is a potent inhibitor of prostanoid-induced platelet aggregation,

Carbocyclic Thromboxane A2(CTA2) is a stable analog of TXA2 which acts as a potent coronary vasoconstrictor at low concentrations. Unlike other vascular TP receptor agonists, CTA2 is a potent inhibitor of prostanoid-induced platelet aggregation,

carbocyclic thromboxane A2.

carbocyclic thromboxane A2.

carfecillin.

carfecillin.

Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of &lt:5 nM, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.Proteasome

Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of &lt:5 nM, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.Proteasome

Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of &lt:5 nM, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.Proteasome

Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of &lt:5 nM, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.Proteasome

Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of &lt:5 nM, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.Proteasome